# Field Alert Report Submission: Questions and Answers Guidance for Industry:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/field-alert-report-submission-questions-and-answers-guidance-for-industry-guidance-for-industry/b554a2c6-8278-4f9a-a91c-72bcdd411715

> FDA guidance document: Field Alert Report Submission: Questions and Answers Guidance for Industry:  Guidance for Industry. Issue date: July 22, 2021. Get complete insights and analysis.

---

## Details

- Title: Field Alert Report Submission: Questions and Answers Guidance for Industry:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2021-07-22
- Last Changed: 2024-11-05
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-2326">FDA-2018-D-2326</a>

## Related Documents

- [Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-antibody-drug-conjugates-guidance-for-industry-guidance-for-industry/ee3ed09c-6580-489f-bb06-0e93f612d604)
- [Q3C(R8) Impurities: Guidance for Residual Solvents   Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/q3cr8-impurities-guidance-for-residual-solvents-guidance-for-industry-guidance-for-industry/5d102000-693a-43cc-8f78-dc661ff31752)
- [Bispecific Antibody Development Programs Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/bispecific-antibody-development-programs-guidance-for-industry/16d40dbb-63de-4441-b656-7949b4a1018d)